Boston Scientific is keeping the ball rolling in pulsed field ablation, posting 177% electrophysiology growth in the third ...

Boston Scientific (BSX) shares fell 5% following news that the company has paused a study for its FARAPULSE PFA system due to ...

The med-tech company with approximately 9,400 employees in Minnesota posted profit and sales that beat Wall Street’s ...

Demand for the pulsed field ablation device drove the company’s electrophysiology sales up 177% in the third quarter compared ...

Despite a trial pause, Boston Scientific's impressive Q3 results and strategic expansions hint at a promising growth ...

Boston Scientific's AVANT GUARD trial evaluates the FARAPULSE PFA System for treating persistent atrial fibrillation, pausing ...

The Farawave NAV ablation catheter and the Faraview software are used with the Farapulse field ablation system to provide ...

Boston Scientific received FDA approval for its navigation-enabled Farawave Nav ablation catheter and clearance for new ...

Boston Scientific increased its annual profit forecast on Wednesday, fueled by strong demand for its cardiac implants, but temporarily halted a pivotal heart equipment study citing unexpected events.

Corporation announced it has received U.S. Food and Drug Administration approval for the navigation-enabled FARAWAVE NAV ...

In this photo illustration, a Boston Scientific Corporation logo seen ... [+] displayed on a smartphone and pc screen in the ...

Analysis of Boston Scientific Corporation's Q3 results, future growth projections, and potential impact of regulatory ...